Back to results
US 2017/0319692 A1Published application
Anti-ar agent and radiation therapy for androgen receptor positive cancer
AssigneeThe Cleveland Clinic Foundation
InventorMohamed Abazeed
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation therapy.
Claims20
A method of treating cancer comprising:
- a) determining that a subject has androgen receptor positive cancer cells;
- b) treating said subject with an anti-androgen receptor agent under conditions such that at least some or most or all of said androgen receptor positive cancer cells are sensitized to radiation therapy;
- and
- c) treating said subject with radiation therapy, wherein said radiation therapy is performed at least 1 hour after said treating with said anti-androgen receptor agent, and wherein said treating causes at least a portion of said androgen receptor positive cancer cells to die.
1 more element
A system comprising:
- a) a radiation therapy device, and
- b) an anti-androgen receptor agent.
Dependencies are inferred from the claim text.